We’re thrilled to spotlight our two entrepreneurs-in-residence (EIRs), Luba Greenwood, J.D. and Dr. Sven Dethlefs. Both Ms. Greenwood and Dr. Dethlefs will work with PureTech’s senior leadership team and board on our program and corporate strategies. As the Founder and Managing Partner of the Dana-Farber Cancer Institute Venture Fund and Binney Street Capital (BSC), and the former CEO and Chair of the Board of Kojin Therapeutics, Ms. Greenwood brings extensive experience to help advance PureTech’s oncology program through the clinic. Dr. Dethlefs, a global pharmaceutical executive with over 25 years of experience, joined PureTech from Teva Pharmaceuticals, where he was EVP and CEO of North America, and his expertise, including as a partner with McKinsey & Company, will help guide PureTech’s IPF and PF-ILD programs through late-stage development. #PureTechPioneers
About us
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
- Website
-
http://www.puretechhealth.com
External link for PureTech Health
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
Locations
-
Primary
6 Tide St
Boston, Massachusetts 02210, US
Employees at PureTech Health
Updates
-
Today our Founded Entity Vedanta Biosciences, Inc. announced the expansion of its leadership team as the company progresses its Phase 3 trial for #Cdiff and Phase 2 trial for #ulcerativecolitis and builds its commercial function https://bit.ly/46oHlVp
-
-
Happy #IndependenceDay! We wish our PureTech community a happy and safe Fourth of July celebration.
-
-
We are delighted to share that Raju Kucherlapati, PhD, distinguished Professor of Medicine at Harvard Medical School, has been appointed permanent Chair of the PureTech Board of Directors. https://bit.ly/45zq5wj
-
-
Today we honor #Juneteenth, a day of profound significance in US history. Earlier this month, we had the privilege of hosting local historian Sean Osborne, PE who highlighted for us the bravery of #QuockWalker (among other heroes) and how his courage led to MA being one of the first states to abolish slavery.
-
-
PureTech Health reposted this
We are pleased to welcome Antony Loebel, M.D., as Chief Medical Officer and President of Clinical Development, and Lana Gladstein, J.D. as General Counsel at Seaport. A CNS drug development expert, Dr. Loebel was the former Chief Executive Officer and Chief Medical Officer at Sunovion Pharmaceuticals. An experienced attorney, Lana brings over two decades of legal expertise, including corporate governance, navigating M&A transactions, licensing and partnerships, and intellectual property matters. Commenting on the appointments, Daphne Zohar, Founder and CEO of Seaport said: “I’m delighted to welcome two more outstanding members to our senior executive team. As we design and run studies to advance our clinical-stage pipeline of novel therapeutics focused on important mental health conditions, Tony’s deep understanding of neuropsychiatric drug development builds on our team’s distinct advantages. We are rapidly growing our company and Lana’s experience across all facets of legal, including corporate governance, transactions, and IP, will be an important resource to Seaport. I’m thrilled to have both Tony and Lana onboard.” https://lnkd.in/exdWvKai
-
-
Our CEO, Bharatt Chowrira, Ph.D., J.D., & Co-founder and President, Eric Elenko Elenko, Ph.D., participated in a fireside chat at the Jefferies Global Healthcare Conference, where they discussed our robust R&D engine. Listen here: https://bit.ly/4c4m6Kb #JefferiesHealthcare
-
-
Our Chief Executive Officer, Bharatt Chowrira, and Co-founder & President, Eric Elenko, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6th, 2024, at 10:00am EDT / 3:00pm BST https://bit.ly/3KfaPuG
-
-
Thank you American Thoracic Society for an incredible #ATS2024. Our team had many insightful interactions, especially at our presentation of the adverse event burden with current treatments for #IPF. We hope to make a difference for patients with idiopathic pulmonary fibrosis, and we look forward to sharing data from our Phase 2b trial of LYT-100 in Q4.
-
-
Congratulations to our Founded Entity Vedanta Biosciences, Inc. on the initiation of the global Phase 3 trial of VE303 for the prevention of recurrent #Cdiff. https://bit.ly/4btIrks
-